The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX stock is upgraded to hold.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Eli Lilly sells Zepbound vials at a discount for people ... which the patients say complicates their cost-saving strategy. Also, to keep the company's discount, patients like Carmichael would ...

Working with these virtual care companies is part of Eli Lilly's broader strategy to make its glucagon ... and diabetes medications Mounjaro and Zepbound. Eli Lilly's foray into telehealth shows ...

Patients taking Zepbound will be able to switch to Wegovy if the Lilly drug is excluded from their coverage, Whitrap said. CVS Health also said Thursday that it will start selling Wegovy at a ...

Eli Lilly has seen US prescriptions for its Zepbound obesity shot surpass Wegovy ... things move in the right direction once you have the strategy right,” he said. “It just feels like there ...

The company announced a new partnership with Eli Lilly’s LillyDirect pharmacy provider ... to receive prescriptions for Zepbound in single-dose vial form directly through the WeightWatchers ...